March 16 2022
The updated results of the OlympiA Trial (NSABP B-55) were presented today at a virtual plenary session of the European Society of Medical Oncology (ESMO) by the Global Study Chair, Andrew Tutt, Professor of Oncology at The Institute of Cancer Research, London, and King’s College London.
These results showed that olaparib significantly improved overall survival (OS) in patients with HER2-negative early breast cancer and germline BRCA mutations.
Click here to read the full Press Release.